DS
NEO icon

David Shaw’s NeoGenomics NEO Stock Holding History

David Shaw’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-30,000
Closed -$365K – 5616
2022
Q1 		$365K Buy
+30,000
New +$631K ﹤0.01% 4551
2021
Q4 		– Sell
-25,000
Closed -$1.21M – 5596
2021
Q3 		$1.21M Hold
25,000
– – ﹤0.01% 3454
2021
Q2 		$1.13M Buy
+25,000
New +$1.11M ﹤0.01% 3441

Other funds holding NEO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

David Shaw's NEO Position: Q2 2026 in Review

David Shaw reduced its NeoGenomics (NEO) stake by 47% in Q2 2026, selling an estimated $19M and leaving 2,194,758 shares worth $32M. The position accounts for 0.02% of the portfolio, ranked #1013.

David Shaw first reported a position in NEO in Q4 2014 and has held it in 31 quarters since. The position peaked at $62.3M in Q4 2025. 265 funds tracked by Wall St. Rank hold NEO as of Q2 2026.

  • David Shaw held 2,194,758 shares of NeoGenomics worth $32M as of Q2 2026.
  • David Shaw sold 1,969,425 NeoGenomics shares in Q2 2026, an estimated $19M.
  • NeoGenomics made up 0.02% of David Shaw's portfolio in Q2 2026, its #1013 holding.
  • David Shaw first reported a position in NeoGenomics in Q4 2014 and has held it in 31 quarters since.
  • David Shaw's NeoGenomics position peaked at $62.3M in Q4 2025.
  • 265 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.